Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics, Inc. (NASDAQ:KROS) has announced it will discontinue all development of cibotercept (KER-012) for ...

Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% ...

Keros Therapeutics, Inc. (NASDAQ:KROS) has announced it will discontinue all development of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) after topline data from the TROPOS Phase ...

Southern Miss' Tucker Stockman had an inkling he would have a chance to be his team’s hero in the NCAA regional elimination ...

Keros Therapeutics (NASDAQ:KROS) discontinues a hypertension drug trial, cuts workforce by 45%, and faces shareholder ...

Keros Therapeutics (NASDAQ:KROS) shares fell on Thursday after the company said it is discontinuing a Phase 2 trial designed to test cibotercept its treatment for pulmonary arterial hypertension.

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...